Abstract: A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.

Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (1) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.

Abstract: The present disclosure is directed to the treatment of Alzheimer's disease by administering 1?,3?-dihydro-2H-spiro[imidazo[1,2?]pyridine-3,2?-inden]-2-one orally at a daily dose of 180 mg as a single active agent or co-administered with donepezil hydrochloride and/or memantine hydrochloride.

Abstract: Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).

Abstract: The present invention provides a method of treating a disease or disorder with at least one SMARCA2/4 degrader, in a subject who are responders to such treatment based on the presence of tumor specific alterations described therein. The present invention also provides the methods for treating prostate cancer in the subjects who are likely to respond to treatment with SMARCA2/4 degraders.

Abstract: The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (Stage III)), and in particular to the treatment of patients whose disease has not progressed following definitive platinum-based chemoradiation therapy.

Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof; or any combination thereof.

Abstract: The Application describes a new target for the treatment of pain and identifies suitable compounds for use in the invention.

Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).

Abstract: The present invention relates to an oral solution formulation or an oral powder for constitution comprising 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazirt-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, or a lactate or malate salt thereof, and a buffer system comprising lactic acid or malic acid.

Abstract: Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.

Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a an agent that blocks Programmed Death-1 receptor (PD-1) and Programmed Death Ligand-1 (PD-L1) signaling and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, kits comprising the compositions and methods of use therefor.

Abstract: Method for treating vitiligo, including active and stable non-segmental vitiligo, using compounds and analogues which inhibit certain kinases including Janus Kinase (JAK), said method comprising the step of administering to the subject in need thereof 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Abstract: The present disclosure provides therapeutic methods of treating a cancer patient with TGO2 and a second therapeutic agent, e.g., TGO2 and an immune checkpoint inhibitor, TGO2 and a COX-2 inhibitor, or TGO2 and an immune checkpoint inhibitor and a COX-2 inhibitor.

Abstract: The disclosure relates to methods of using selective inhibitors of VEGFR2 and FGFR1 to promote lipid storage and fat increase, and for treatment of a wasting syndrome.

Abstract: The present invention provides a method for treating a liver disorder or lipid disorder in a subject in need thereof with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, a stereoisomer, a salt thereof, or a morphic form thereof.

Abstract: Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.

Abstract: The disclosure provides, inter alia, topical pharmaceutical compositions comprising active agents, methods for increasing tear production using the topical pharmaceutical compositions, and methods for treating dry eye disorders using the topical pharmaceutical compositions.

Abstract: The present invention relates to stable pharmaceutical compositions for parenteral administration comprising aprepitant. The present invention further relates to a method for manufacturing the composition as well as to the use of these compositions. Also included are stable pharmaceutical compositions for parenteral administration comprising aprepitant and palonosetron. The pharmaceutical compositions are stable oil-in-water emulsions for parenteral administration and are particularly useful for the prevention and control of acute and delayed chemotherapy-induced nausea and vomiting (CINV), for the prevention of postoperative nausea and vomiting (PONV), and/or for the prevention of radiation induced nausea and vomiting (RINV).

Abstract: Provided herein are ophthalmic pharmaceutical formulations comprising a rifamycin compound. Also provided herein are methods of treating ocular diseases or disorders by administering such ophthalmic formulations.

Abstract: Heterocyclic compounds of Formula (I) are described herein along with their stereoisomers and pharmaceutically acceptable salts thereof. The compounds described herein, their stereoisomers, and pharmaceutically acceptable salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis.

Abstract: Provided herein is process of preparing metopimazine acid by reacting metopimazine, or a pharmaceutically acceptable salt thereof, with human microsomal liver amidase. Also provided herein are methods of treating gastroparesis in a human subject in need thereof with metopimazine, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent which is not metabolized by human microsomal liver amidase and/or human liver cytosolic aldehyde oxidase.

Abstract: Aqueous pharmaceutical compositions, suitable for topical ophthalmic administration to a mammal, that comprise a therapeutically effective amount of a prostaglandin, less than 0.3% w/v, and no added benzalkonium chloride, are provided. Such compositions are useful in methods comprising their topical administration to mammalian subjects, e.g., humans and reducing intraocular pressure and/or ocular hyperemia in the patient. Such compositions are also useful in methods comprising their topical administration to mammalian subjects, e.g., humans and promoting eyelash growth in the patient.

Abstract: This invention discloses uses for estradiol in preparing anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma products. This invention provides uses for estradiol in preparing anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma products. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug estradiol, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that estradiol has a new use as an anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma medication, thus achieving a new purpose for an old drug.

Abstract: This invention provides for a method of treating secondary adrenal insufficiency by co-administrating therapeutically effective amounts of a glucocorticoid and a glucocorticoid receptor antagonist to the patient in need thereof. In some embodiments, the method includes the proviso that the patient not be otherwise in need of treatment with a glucocorticoid and a glucocorticoid receptor antagonist. The treatment method can increase the patient's morning or basal cortisol level to at least about 12 ?g/dL or a standard control level, and in turn, expedite significantly the recovery of the HPA axis. The method provided herein can improve health outcomes and life-threatening complications associated with secondary adrenal insufficiency.

Abstract: Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone undecanoate are provided.

Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.

Abstract: Compositions and methods for the delivery of progestin hormones that have binding affinity to the Sex Hormone Binding Globulin (SHBG) are disclosed. The compositions combine such progestins with non-progestin SHBG ligands to displace at least part of the progestin from SHBG in the blood plasma, thereby increasing its bioavailability. Also disclosed are methods to modulate progestin and estrogen levels in the blood through the use of SHBG binding and displacement, to optimize the effectiveness of formulations for contraception and minimize the side effects and adverse events.

Abstract: Provided is a pharmaceutical composition for delivery of an active agent to an eye. The pharmaceutical composition may comprise a lipid mixture; an active agent and a biocompatible hydrogel. The pharmaceutical composition achieves a prolonged therapeutic effect as well as reduced side effects. Also provided is a method of delivering an active agent in the pharmaceutical composition to an eye of a subject in need thereof.

Abstract: The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.

Abstract: Disclosed are nut and seed products comprising a coating, wherein the coating comprises a nutritional additive, as well as methods of preparing said coated nut and seed products.

Abstract: A topical therapeutic composition comprising naproxen and menthol. The naproxen penetrates through the skin for local effect against pain and inflammation (e.g. at a joint) as well as systemic absorption. The menthol could work as both an analgesic and to enhance skin penetration of the naproxen. The composition could further comprise other therapeutic ingredients. For example, the composition could further comprise a different analgesic such as camphor or methyl salicylate. In another example, the composition could further comprise a botanical ingredient such as Arnica Montana or Burdock root. In another example, the composition could further comprise a different skin penetration enhancing agent such as DMSO. The topical therapeutic composition could be used for the treatment of various conditions such as neuromuscular, skeletal, or arthritic disorders, or for the treatment or prevention of Alzheimer disease.

Abstract: The disclosure relates to methods for treating brain injuries that include administering to a patient a first dosage of about 100 mg to about 500 mg of cannabidiol (CBD) and administering to the patient, concomitantly with the first dosage, a second dosage of about 1 to about 10 milligrams of Psilocybin.

Abstract: An orally administrable formulation is provided. The formulation comprises a hydrophilic polymeric base incorporating a pharmaceutical component. The pharmaceutical component comprises a pharmaceutical compound selected from a cannabinoid, a psychedelic compound or a mixture thereof and an absorption enhancer to enhance absorption of the pharmaceutical agent by the oral mucosa.

Abstract: A composition for ameliorating periodontal tissue containing plasmalogen extracted from animal tissues such as shellfish, sea squirts and birds.

Abstract: This invention relates generally to neurodegenerative diseases and conditions (e.g., Alzheimer's disease) characterized with dysfunctional energetic function, unregulated microglia phagocytic activity and other related de-regulated biological functions. This invention further relates to methods and compositions for treating such neurodegenerative diseases and conditions with pharmaceutical compositions capable of protecting neurons from cell death and unregulated microglia phagocytic activity.

Abstract: Use of baicalin in preparation of a medicament for resisting pseudorabies virus (PRV) and diseases caused thereby is provided. The present disclosure relates to the technical field of medicine. It is found for the first time in the present disclosure that the baicalin has anti-PRV activity, has no obvious toxicity to cells in the using concentration range of 31.25-125 ?M, and shows an obvious inhibitory effect on PRV replication and proliferation in the concentration range of 62.5-125 ?M. It can be foreseen that the baicalin can be developed as a safe and effective anti-PRV medicament, and a novel anti-PRV medicament under existing application conditions of the baicalin, with an excellent application prospect.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

Abstract: Characterization of drug-drug interaction properties and pharmacological properties of maribavir is useful to inform potential drug-drug interactions and dosing strategies when administering with co-medications.

Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for treating solid tumors. In a specific embodiment, a method for treating a solid tumor in a patient having cancer comprises the step of administering to the patient a demethylating agent, a histone deacetylase (HDAC) inhibitor and a checkpoint inhibitor.

Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

Abstract: Described herein are nanoparticle compositions and methods for pH-specific release and targeted delivery of therapeutics with enhanced bioavailability. In some embodiments, methods are described for generating carbon nanoparticles (CNPs) that can release payload in acidic pH environments.

Abstract: The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis.

Abstract: The present disclosure provides a methylcobalamin ophthalmic preparation and a preparation method and use thereof, belonging to the technical field of eye drops. The methylcobalamin ophthalmic preparation includes a methylcobalamin technical (TC) and proanthocyanidin, where the methylcobalamin TC and the proanthocyanidin have a mass ratio of (0.02-0.1):(0-0.5); and a dosage form of the methylcobalamin ophthalmic preparation is one or more of a drop, a hydrogel, and a liposome. In the present disclosure, the methylcobalamin is used as an active ingredient, and the proanthocyanidin is used as a synergist of the methylcobalamin; the methylcobalamin ophthalmic preparation can promote corneal nerve regeneration, accelerate corneal epithelial healing, and effectively inhibit corneal neovascularization to improve corneal perception.

Abstract: The present disclosure provides a method for extracting a Lactarius Hatsudake Tanaka polysaccharide compound, and relates to the field of active substance extraction.

Abstract: The disclosure is generally related to therapeutic compositions and methods for use in the treatment of somatosensory conditions, including pain and pruritis. In some aspects, the compositions comprise hyaluronic acid having a therapeutically effective molecular weight and one or more transdermal delivery agents.

Abstract: The present disclosure describes formulations and methods for hydrating dry eyes. The formulations comprise at least one natural humectant, at least one amino acid, and at least one vitamin, wherein the formulation is preservative free, and may provide effective hydration, lubrication, and/or nourishment of the eyes.

Abstract: A method for the treatment of bone marrow edema in a mammal comprising administering an effective amount of a polysulfated polysaccharide including salts thereof, to a mammal in need of such treatment.

Abstract: The invention describes ophthalmic pharmaceutical formulations comprising pharmaceutical ingredients to address DED symptoms. In one aspect of the invention, an ophthalmic pharmaceutical formulation comprises: 1) lubricity-promoting ingredient(s) such as those listed in the FDA over the counter (OTC) monograph for ophthalmics as demulcents and 2) surfactant(s) that solubilize lipids, assist in lubrication, and assist in easily spreading over hydrophobic surfaces; and/or 3) lipid and/or oil ingredient(s) that assist in film formation and the spreading of tear fluid while promoting (or at least not inhibiting) lubrication; and/or 4) mucoadhesive and viscosity promoting polymer(s) that demonstrate shear thinning flow behavior. The pharmaceutical ingredients and osmoprotectant/tonicity ingredients are combined with ingredients that provide direct to the eye nutritional support that is comprehensive in nature.